Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALML3 | P27482 | 6/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | MAOA | P21397 | 9/20 | 0.45 |
| ▸ | MAOB | P27338 | 2/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | F10 | P00742 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3034994 | 0.91 | CALML3 (0.47) | CALML3CYP2C19CYP3A4MAOAMAOB | |
| SCHEMBL3032898 | 0.86 | CALML3 (0.44) | CALML3CYP2C19CYP3A4MAOAMAOB | |
| SCHEMBL6797699 | 0.85 | MAOA (0.58) | CALML3CYP2C19CYP3A4MAOAMAOB | |
| SCHEMBL6642797 | 0.84 | CALML3 (0.47) | CALML3CYP2C19CYP3A4MAOAMAOB | |
| SCHEMBL27579383 | 0.84 | CALML3 (0.48) | CALML3CYP2C19CYP3A4MAOAMAOB | |
| SCHEMBL6671547 | 0.82 | CALML3 (0.52) | CALML3CYP2C19CYP3A4MAOAMAOB | |
| SCHEMBL3041346 | 0.81 | CALML3 (0.50) | CALML3CYP2C19CYP3A4MAOAMAOB | |
| SCHEMBL3036196 | 0.80 | CALML3 (0.49) | CALML3CYP2C19CYP3A4MAOAMAOB | |
| SCHEMBL3041844 | 0.78 | CALML3 (0.47) | CALML3CYP2C19CYP3A4MAOAMAOB | |
| SCHEMBL6087059 | 0.78 | CALML3 (0.47) | CALML3CYP2C19CYP3A4MAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040147760-A1 | N-aryl-2-oxazolidinone-5-carboxamides and their derivatives | PHARMACIA & UPJOHN COMPANY | 2004-07-29 | — | — | US | claimed |
| US-7645781-B2 | N-aryl-2-oxazolidinone-5-carboxamides and their derivatives | PFIZER INC (US) | 2010-01-12 | — | — | US | disclosed |
| US-20070015801-A1 | N-aryl-2-oxazolidinone-5-carboxamides and their derivatives | THOMAS RICHARD C | 2007-01-18 | — | — | US | disclosed |
| US-7141588-B2 | N-aryl-2-oxazolidinone-5-carboxamides and their derivatives | PFIZER, INC. (US) | 2006-11-28 | — | — | US | disclosed |
| US-20040147760-A1 | N-aryl-2-oxazolidinone-5-carboxamides and their derivatives | PHARMACIA & UPJOHN COMPANY | 2004-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147760-A1 | N-aryl-2-oxazolidinone-5-carboxamides and their derivatives | OXA1L, AADAC, MT-ND5 | CALML3 3149/4885CYP2C19 359/4885CYP3A4 582/4885 |
| US-20070015801-A1 | N-aryl-2-oxazolidinone-5-carboxamides and their derivatives | OXA1L, AADAC, MT-ND5 | CALML3 3149/4885CYP2C19 359/4885CYP3A4 582/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.